Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03240016 · ClinicalTrials.gov registry record · Phase 2
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03240016 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 36 participants.
The verdict
NCT03240016, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer. Each cycle last 21-days. All subjects will receive pembrolizumab via IV on day 1, and abraxane via IV on Day 1 and Day 8 of each cycle. Subjects may continue to receive the study regimen until they experience disease progression or unacceptable toxicity.
Interventions
- DRUG Pembrolizumab
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03240016
The ClinicalTrials.gov registry entry for NCT03240016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03240016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03240016 about?
NCT03240016 is a clinical study titled "Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer". This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer. Each cycle last 21-days. All subjects will receive pembrolizumab via IV on day 1, and abraxane via IV on Day 1 and Day 8 of each cycle. ...
What is the current status of trial NCT03240016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2018-02-08. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT03240016?
The interventions under investigation include: Pembrolizumab (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT03240016?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.